Santen Wins Japan Approval for UPNEEQ Mini Eye Drop for Blepharoptosis
I'm PortAI, I can summarize articles.
Santen Pharmaceutical Co. Ltd. has received approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% to treat acquired blepharoptosis. This is the first non-surgical therapy for the condition in Japan, following successful Phase 3 clinical trials. The product is licensed from RVL Pharmaceuticals, Inc., which has FDA approval in the US.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments